Literature DB >> 16024609

Synergistic induction of DOC-2/DAB2 gene expression in transitional cell carcinoma in the presence of GATA6 and histone deacetylase inhibitor.

Jian Zhou1, Gina Hernandez, Szu-Wei Tu, Jessica Scholes, Hong Chen, Ching-Ping Tseng, Jer-Tsong Hsieh.   

Abstract

The down-regulation of DOC-2/DAB2 gene, which encodes a unique phosphoprotein modulating signal pathways elicited by exogenous stimuli, is often associated with several cancer types; however, the underlying mechanism is still unknown. Dramatically different expression levels of DOC-2/DAB2 mRNA and protein are observed among several human transitional cell carcinoma (TCC) cell lines, suggesting that transcriptional regulation may play a role in these cells. In this study, we have shown that the histone acetylation status associated with the 5' upstream regulatory sequence of DOC-2/DAB2 gene is one of the key determinants for its gene expression. In addition, GATA6 but not other GATA family members, such as GATA2 and GATA4, can specifically induce DOC-2/DAB2 promoter activity, although GATA transcription factors share a very similar DNA-binding sequence. We also show that increased histone acetylation and the presence of GATA6 have a synergistic effect on DOC-2/DAB2 promoter activity, which results in the elevation of DOC-2/DAB2 protein expression. Thus, we conclude that transcriptional regulation of DOC-2/DAB2 gene in human TCC is determined by histone acetylation and a specific transcription factor (i.e., GATA6), which underlie the reduced DOC-2/DAB2 protein expression in TCC cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16024609     DOI: 10.1158/0008-5472.CAN-04-3672

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Deficiency of Dab2 (Disabled Homolog 2) in Myeloid Cells Exacerbates Inflammation in Liver and Atherosclerotic Plaques in LDLR (Low-Density Lipoprotein Receptor)-Null Mice-Brief Report.

Authors:  Samantha E Adamson; Renata Polanowska-Grabowska; Kathryn Marqueen; Rachael Griffiths; Jerry Angdisen; Sarah R Breevoort; Ira G Schulman; Norbert Leitinger
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-03-29       Impact factor: 8.311

2.  Loss of disabled-2 expression is an early event in esophageal squamous tumorigenesis.

Authors:  Kumar Anupam; Chatopadhyay Tusharkant; Siddhartha Datta Gupta; Ralhan Ranju
Journal:  World J Gastroenterol       Date:  2006-10-07       Impact factor: 5.742

3.  Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma.

Authors:  Joanna H Tong; David C Ng; Shuk L Chau; Ken K So; Patrick P Leung; Tin L Lee; Raymond W Lung; Michael W Chan; Anthony W Chan; Kwok W Lo; Ka F To
Journal:  BMC Cancer       Date:  2010-06-03       Impact factor: 4.430

4.  Short chain fatty acids delay the development of hepatocellular carcinoma in HBx transgenic mice.

Authors:  Noreen McBrearty; Alla Arzumanyan; Eugene Bichenkov; Salim Merali; Carmen Merali; Mark Feitelson
Journal:  Neoplasia       Date:  2021-05-01       Impact factor: 5.715

5.  Loss of Disabled-2 Expression in Pancreatic Cancer Progression.

Authors:  Barbara A Hocevar
Journal:  Sci Rep       Date:  2019-05-17       Impact factor: 4.379

Review 6.  Frequent loss expression of dab2 and promotor hypermethylation in human cancers: a meta-analysis and systematic review.

Authors:  Ziyin Zhang; Yihua Chen; Jianjian Tang; Xuemei Xie
Journal:  Pak J Med Sci       Date:  2014-03       Impact factor: 1.088

7.  Low disabled-2 expression promotes tumor progression and determines poor survival and high recurrence of esophageal squamous cell carcinoma.

Authors:  Wen-Lun Wang; Wei-Lun Chang; Hsiao-Bai Yang; Yu-Chi Wang; I-Wei Chang; Ching-Tai Lee; Chi-Yang Chang; Jaw-Town Lin; Bor-Shyang Sheu
Journal:  Oncotarget       Date:  2016-11-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.